DOCSLIB.ORG

Recent FDA News Advancing Treatments in Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent FDA News Advancing Treatments in Oncology Recent FDA News Advancing Treatments in Oncology Oncology Drug Targeting a Key Genetic and AST liver tests every 2 weeks during the first month of treatment, Driver of Cancer Approved then monthly and as clinically indicated. Women who are pregnant or The FDA granted Accelerated Approval to larotrectinib, a treatment for breastfeeding should not take larotrectinib because it may cause harm adult and pediatric patients whose cancers have a specific biomarker. to a developing fetus or newborn baby. Patients should report signs of This is the second time the agency has approved a cancer treat- neurologic reactions such as dizziness. ment based on a common biomarker across different types of tumors The FDA granted this application Priority Review and Breakthrough rather than the location in the body where the tumor originated. The Therapy designation. Larotrectinib also received Orphan Drug desig- approval marks a new paradigm in the development of cancer drugs nation, which provides incentives to assist and encourage the develop- that are “tissue agnostic.” It follows the policies that the FDA developed ment of drugs for rare diseases. in a guidance document released earlier this year. Larotrectinib is indicated for the treatment of adult and pediatric Venetoclax Combination Approved for Adult patients with solid tumors that have a neurotrophic receptor tyrosine AML Patients kinase (NTRK) gene fusion without a known acquired resistance mu- The FDA recently granted Accelerated Approval to venetoclax in com- tation, are metastatic, or where surgical resection is likely to result in bination with azacitidine or decitabine or low-dose cytarabine for severe morbidity and have no satisfactory alternative treatments or the treatment of newly diagnosed acute myeloid leukemia (AML) in that have progressed following treatment. adults who are age 75 years or older, or who have comorbidities that “[This] approval marks another step in an important shift toward preclude use of intensive induction chemotherapy. treating cancers based on their tumor genetics rather than their site of Approval was based on two open-label, non-randomized trials in origin in the body,” said FDA Commissioner Scott Gottlieb, MD. “This patients with newly diagnosed AML who were >75 years of age or had new site-agnostic oncology therapy isn’t specific to a cancer arising in comorbidities that precluded the use of intensive induction chemo- a particular body organ, such as breast or colon cancer. Its approval therapy. Efficacy was established based on the rate of complete remis- reflects advances in the use of biomarkers to guide drug development sion (CR) and CR duration. and the more targeted delivery of medicine. Study M14-358 (NCT02203773) was a non-randomized, open- “We now have the ability to make sure that the right patients get label clinical trial of venetoclax in combination with azacitidine the right treatment at the right time. This type of drug development (n=67) or decitabine (n=13) in newly diagnosed patients with AML. program, which enrolled patients with different tumors but a common In combination with azacitidine, 25 patients achieved a CR (37%, 95% gene mutation, wouldn’t have been possible a decade ago because we CI: 26, 50) with a median observed time in remission of 5.5 months knew a lot less about such cancer mutations,” he continued. “Using our (range: 0.4-30 months). In combination with decitabine, seven pa- breakthrough therapy designation and accelerated approval processes, tients achieved a CR (54%, 95% CI: 25, 81) with a median observed we support innovation in precision oncology drug development and time in remission of 4.7 months (range: 1.0-18 months). The observed the evolution of more targeted and effective treatments for cancer pa- time in remission is the time from start of CR to data cut-off date or tients. This is especially true when it comes to pediatric cancers. relapse from CR. “We’re committed to continuing to advance a more modern frame- Study M14-387 (NCT02287233) was a non-randomized, open- work of clinical trial designs that support more targeted innovations label trial of venetoclax in combination with low-dose cytarabine across disease types based on our growing understanding of the un- (n=61) in newly diagnosed patients with AML, including patients derlying biology of diseases like cancer.” with previous exposure to a hypomethylating agent for an antecedent Research has shown that the NTRK genes, which encode for TRK pro- hematologic disorder. In combination with low-dose cytarabine, 13 teins, can become fused to other genes abnormally, resulting in growth patients achieved a CR (21%, 95% CI: 12, 34) with a median observed signals that support the growth of tumors. NTRK fusions are rare but time in remission of 6 months (range: 0.03-25 months). occur in cancers arising in many sites of the body. Prior to this approval, The most common adverse reactions (≥30%) to venetoclax in com- there had been no treatment for cancers that frequently express this mu- bination with azacitidine or decitabine or low-dose cytarabine were tation, like mammary analogue secretory carcinoma, cellular or mixed nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile congenital mesoblastic nephroma, and infantile fibrosarcoma. neutropenia, fatigue, vomiting, peripheral edema, pneumonia, dyspnea, The efficacy of larotrectinib was studied in three clinical trials that hemorrhage, anemia, rash, abdominal pain, sepsis, back pain, myalgia, included 55 pediatric and adult patients with solid tumors that had an dizziness, cough, oropharyngeal pain, pyrexia, and hypotension. identified NTRK gene fusion without a resistance mutation and were The recommended venetoclax dose depends upon the combination metastatic or where surgical resection was likely to result in severe regimen. morbidity. These patients had no satisfactory alternative treatments This indication is approved under Accelerated Approval and con- or had cancer that progressed following treatment. tinued approval for this indication may be contingent upon verifica- Larotrectinib demonstrated a 75 percent overall response rate tion and description of clinical benefit in confirmatory trials. FDA across different types of solid tumors. These responses were durable, granted this application Priority Review, Breakthrough Therapy with 73 percent of responses lasting at least 6 months, and 39 percent Designation, and Orphan Product Designation. lasting a year or more at the time results were analyzed. Examples of The ongoing phase III studies, VIALE-A (NCT02993523) and tumor types with an NTRK fusion that responded to larotrectinib in- VIALE-C (NCT03069352), evaluate venetoclax in combination with clude soft tissue sarcoma, salivary gland cancer, infantile fibrosarcoma, azacitidine or low-dose cytarabine with overall survival as the primary thyroid cancer, and lung cancer. endpoint and are intended as the confirmatory trials. Larotrectinib received an accelerated approval, which enables the FDA to approve drugs for serious conditions to fill an unmet med- Atezolizumab With Chemo & Bevacizumab ical need using clinical trial data that is thought to predict a clini- for Metastatic Non-Squamous NSCLC cal benefit to patients. Further clinical trials are required to confirm The FDA recently approved atezolizumab in combination with larotrectinib’s clinical benefit and the sponsor is conducting or plans bevacizumab, paclitaxel, and carboplatin for the first-line treatment to conduct these studies. of patients with metastatic non-squamous, non-small cell lung cancer Common side effects reported by patients receiving larotrectinib (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. in clinical trials include fatigue, nausea, cough, constipation, diarrhea, Approval was based on the IMpower150 trial (NCT02366143), an dizziness, vomiting, and increased AST and ALT enzyme blood levels open-label, randomized (1:1:1), three-arm trial enrolling 1,202 pa- in the liver. Health care providers are advised to monitor patient ALT Continued on page 34 oncology-times.com Oncology Times 33 The NCI estimates that approximately 19,520 people will be diag- FDA UPDATES nosed with AML this year; approximately 10,670 patients with AML continued from page 33 will die of the disease in 2018. The efficiency of gilteritinib was studied in a clinical trial of 138 patients with relapsed or refractory AML having a confirmed FLT3 tients receiving first-line treatment for metastatic NSq NSCLC. Eighty- mutation. Twenty-one percent of patients achieved complete remis- seven percent (1,045 patients) were identified as not having EGFR or sion or complete remission with partial hematologic recovery with ALK tumor mutations. The trial was designed to conduct comparisons treatment. Of the 106 patients who required red blood cell or platelet between each of the atezolizumab-containing arms with the control transfusions at the start of treatment with gilteritinib, 31 percent be- arm. Patients were randomized to receive the following: came transfusion-free for at least 56 days. • atezolizumab, carboplatin, paclitaxel, and bevacizumab (4-drug Common side effects reported by patients in clinical trials were regimen); myalgia/arthralgia, fatigue, and liver transaminase. Health care pro- • atezolizumab, carboplatin, and paclitaxel (3-drug regimen); or viders are advised to monitor patients for posterior reversible en- • carboplatin, paclitaxel, and bevacizumab (control arm). cephalopathy syndrome, prolonged QT interval,
Load more

Recommended publications
  • The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
    Published OnlineFirst May 2, 2019; DOI: 10.1158/2159-8290.CD-19-0125 RESEARCH ARTICLE The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells Tamilla Nechiporuk1,2, Stephen E. Kurtz1,2, Olga Nikolova2,3, Tingting Liu1,2, Courtney L. Jones4, Angelo D’Alessandro5, Rachel Culp-Hill5, Amanda d’Almeida1,2, Sunil K. Joshi1,2, Mara Rosenberg1,2, Cristina E. Tognon1,2,6, Alexey V. Danilov1,2, Brian J. Druker1,2,6, Bill H. Chang2,7, Shannon K. McWeeney2,8, and Jeffrey W. Tyner1,2,9 ABSTRACT To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations.
    [Show full text]
  • Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity
    Published OnlineFirst July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia Jun Ma1, Shoujing Zhao1, Xinan Qiao1, Tristan Knight2,3, Holly Edwards4,5, Lisa Polin4,5, Juiwanna Kushner4,5, Sijana H. Dzinic4,5, Kathryn White4,5, Guan Wang1, Lijing Zhao6, Hai Lin7, Yue Wang8, Jeffrey W. Taub2,3, and Yubin Ge3,4,5 Abstract Purpose: To investigate the efficacy of the combination of with venetoclax. Changes of Mcl-1 transcript levels were the FLT3 inhibitors midostaurin or gilteritinib with the Bcl-2 assessed by RT-PCR. inhibitor venetoclax in FLT3-internal tandem duplication Results: The combination of midostaurin or gilteritinib (ITD) acute myeloid leukemia (AML) and the underlying with venetoclax potently and synergistically induces apo- molecular mechanism. ptosis in FLT3-ITD AML cell lines and primary patient Experimental Design: Using both FLT3-ITD cell lines and samples. The FLT3 inhibitors induced downregulation of primary patient samples, Annexin V-FITC/propidium iodide Mcl-1, enhancing venetoclax activity. Phosphorylated-ERK staining and flow cytometry analysis were used to quantify cell expression is induced by venetoclax but abolished by the death induced by midostaurin or gilteritinib, alone or in combination of venetoclax with midostaurin or gilteritinib. combination with venetoclax. Western blot analysis was per- Simultaneous downregulation of Mcl-1 by midostaurin or formed to assess changes in protein expression levels of gilteritinib and inhibition of Bcl-2 by venetoclax results in members of the JAK/STAT, MAPK/ERK, and PI3K/AKT path- "free" Bim, leading to synergistic induction of apoptosis.
    [Show full text]
  • Role of Tafazzin in Hematopoiesis and Leukemogenesis
    Role of Tafazzin in Hematopoiesis and Leukemogenesis by Ayesh Seneviratne A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by Ayesh Seneviratne 2020 Role of Tafazzin in Hematopoiesis and Leukemogenesis Ayesh Seneviratne Doctor of Philosophy Institute of Medical Science University of Toronto 2020 Abstract Tafazzin (TAZ) is a mitochondrial transacylase that remodels the mitochondrial cardiolipin into its mature form. Through a CRISPR screen, we identified TAZ as necessary for the growth and viability of acute myeloid leukemia (AML) cells. Genetic inhibition of TAZ reduced stemness and increased differentiation of AML cells both in vitro and in vivo. In contrast, knockdown of TAZ did not impair normal hematopoiesis under basal conditions. Mechanistically, inhibition of TAZ decreased levels of cardiolipin but also altered global levels of intracellular phospholipids, including phosphatidylserine, which controlled AML stemness and differentiation by modulating toll-like receptor (TLR) signaling (Seneviratne et al., 2019). ii Acknowledgments Firstly, I would like to thank Dr. Aaron Schimmer for his guidance and support during my PhD studies. I really enjoyed our early morning meetings where he provided much needed perspective to navigate the road blocks of my project, whilst continuing to push me. It was a privilege to be mentored by such an excellent clinician scientist. I hope to continue to build on the skills I learned in Dr. Schimmer’s lab as I progress on my path to become a clinician scientist. Working in the Schimmer lab was a wonderful learning environment. I would like to especially thank Dr.
    [Show full text]
  • Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML
    ______________________________________________________________________________ Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML Naval Daver, MD Associate Professor Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas This is a study that we designed with the AbbVie and Astellas teams as well as lead investigators at other sites in the United States. The study combines two very active drugs in AML, one being a BCL- 2 inhibitor, venetoclax, that is approved in the frontline setting as a combination of azacitidine or low-dose cytarabine with venetoclax for older AML, not suitable for induction; the other is a highly potent selective FLT3 inhibitor that targets both FLT3 ITD and TKD as well as dual mutation and has been approved in the relapsed/refractory setting as a single agent, the drug is called gilteritinib. The approval of gilteritinib was based on a randomized phase 3 study that showed that single-agent gilteritinib was able to produce higher response rates, bone marrow responses, CR/CRh, as well as significantly improved overall survival as compared to standard-of-care high-dose chemotherapy or epigenetic therapy. One of the big questions is, why did we do this combination? Well, one reason is that there is actually very potent preclinical synergy for the FLT3 inhibitors, gilteritinib, but also for quizartinib with venetoclax, and our group has done studies in the lab, as have AbbVie, Astellas, and Genentech teams that support a very high degree of synthetic lethality when you combine next-generation FLT3 inhibitors with the BCL-2 inhibitors such as venetoclax. Also, important to note that one of the major mechanisms of resistance or relapse post-venetoclax is MCL1 upregulation, and the FLT3 inhibitors block MCL1, thereby blocking the escape or relapsed potential by using single-agent venetoclax.
    [Show full text]
  • Combination Therapies Involving Gilteritinib and Venetoclax
    Combination Therapies Involving Gilteritinib and Venetoclax Keith W. Pratz, MD Assistant Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland Welcome to Managing AML. I am Dr. Keith Pratz, and I am live at the ASH Annual Meeting in Atlanta, Georgia. Today I will be reviewing two clinical trial presentations: the first is the preliminary results of the phase 1 study of gilteritinib in patients with newly diagnosed acute myeloid leukemia, the second being an updated presentation on the safety and efficacy of venetoclax with decitabine or azacitidine in newly diagnosed, unfit AML patients. Let us begin with the preliminary results of the phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia. This study involves the incorporation of a tyrosine kinase inhibitor targeting FLT3, which is one of the more common mutations in acute myeloid leukemia conferring poor overall outcomes, with standard induction chemotherapy of cytarabine and idarubicin. The study so far has accrued 50 patients since December of 2015. The background is that we are hopeful that the addition of a tyrosine kinase inhibitor to chemotherapy will improve the quality of remissions and overall survival in patients with this difficult-to-treat disease. The results that we will present show that patients achieved remission at a rate of 100% in patients with FLT3 leukemia in this small subset of patients. We had 21 patients with FLT3 mutations, most of which were ITD mutations; and 19 out of the 21 patients achieved a complete remission with full count recovery, and two other patients achieved complete remission with incomplete count recovery.
    [Show full text]
  • New Drug Update
    Disclosures I have nothing to disclose. New Drug Update JORDAN BASKETT, PHARMD, BCOP CLINICAL ONCOLOGY PHARMACIST DUKE UNIVERSITY HOSPITAL Recently Approved Agents for Leukemia & Lymphoma Objectives Duvelisib September 2018 CLL/SLL, FL Calaspargase pegol-mknl December 2018 ALL 1. Review pharmacology of newly approved oncology Blastic plasmacytoid agents Tagraxofusp-erzs December 2018 dendritic cell neoplasm 2. Discuss literature supporting approval of the agents Ivosidenib July 2018 AML, IDH1+ 3. Identify clinical pearls for new agents Gilteritinib November 2018 AML, FLT3+ 4. Evaluate place in therapy for newly approved agents Glasdegib November2018 AML Moxetumomab September 2018 Hairy cell leukemia pasudotox-tdfk Mycosis fungoides or Mogamulizumab-kpkc August 2018 Sézary syndrome Duvelisib (Copiktra®) Compared to Idelalisib Approved Duvelisib Idelalisib • September 2018 PI3K-δ and PI3K-γ inhibitor PI3K-δ inhibitor MOA • Inhibits PI3K-δ and PI3K-γ in normal and malignant B-cells Monotherapy In combination with rituximab for CLL/SLL Indication BBW: BBW: • Infection • Hepatotoxicity • Relapsed/refractory CLL/SLL and FL after ≥ 2 prior systemic therapies • Diarrhea, colitis (18%) • Diarrhea, colitis (14%) Dosing & Administration • Cutaneous reactions • Intestinal perforation • Pneumonitis (5%) • Pneumonitis (4%) • 25 mg PO BID Administer Pneumocystis jirovecii (PJP) prophylaxis during treatment and until absolute CD4+ T cell count is > 200 cells/uL Consider antiviral prophylaxis for cytomegalovirus reactivation Copiktra (duvelisib) [package insert]. Needham, MA: Verastem, Inc; 2018. Flinn IW, et al. Blood 2018;132(23):2446-2455. Furman RR, et al. N Engl J Med 2014;370(11):997-1007. 1 Calaspargase pegol-mknl Audience Response #1 (AsparlasTM) How does the mechanism of action for duvelisib differ from idelalisib? Approved A.
    [Show full text]
  • New Directions for Emerging Therapies in Acute Myeloid Leukemia: the Next Chapter Naval Daver 1,Andrewh.Wei2, Daniel A
    Daver et al. Blood Cancer Journal (2020) 10:107 https://doi.org/10.1038/s41408-020-00376-1 Blood Cancer Journal REVIEW ARTICLE Open Access New directions for emerging therapies in acute myeloid leukemia: the next chapter Naval Daver 1,AndrewH.Wei2, Daniel A. Pollyea3,AmirT.Fathi4,PareshVyas 5 and Courtney D. DiNardo 1 Abstract Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, followed by consolidation therapy, including allogeneic stem cell transplantation, to prolong remission. In recent years, there has been a significant shift toward the use of novel and effective, target- directed therapies, including inhibitors of mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase (IDH), the B-cell lymphoma 2 inhibitor venetoclax, and the hedgehog pathway inhibitor glasdegib. In older patients the combination of a hypomethylating agent or low-dose cytarabine, venetoclax achieved composite response rates that approximate those seen with standard induction regimens in similar populations, but with potentially less toxicity and early mortality. Preclinical data suggest synergy between venetoclax and FLT3- and IDH-targeted therapies, and doublets of venetoclax with inhibitors targeting these mutations have shown promising clinical activity in early stage trials. Triplet regimens involving the hypomethylating agent and venetoclax with FLT3 or IDH1/2 inhibitor, the TP53- modulating agent APR-246 and magrolimab, myeloid cell leukemia-1 inhibitors, or immune therapies such as CD123 antibody-drug conjugates and programmed cell death protein 1 inhibitors are currently being evaluated. It is hoped that such triplets, when applied in appropriate patient subsets, will further enhance remission rates, and more importantly remission durations and survival.
    [Show full text]
  • In FLT3-Mutated Relapsed/Refractory AML
    POST-ASH Issue 4, 2016 Phase I/II Trial of Gilteritinib (ASP2215) in FLT3-Mutated Relapsed/Refractory AML For more visit ResearchToPractice.com/5MJCASH2016 CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists. Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unmatched and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to
    [Show full text]
  • 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors
    PHARMACY POLICY – 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Aug. 1, 2021 RELATED MEDICAL POLICIES: Last Revised: July 9, 2021 5.01.517 Use of Vascular Endothelial Growth Factor Receptor (VEGF) Inhibitors and Replaces: N/A Other Angiogenesis Inhibitors in Oncology Patients 5.01.518 BCR-ABL Kinase Inhibitors 5.01.544 Prostate Cancer Targeted Therapies 5.01.589 BRAF and MEK Inhibitors 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors Select a hyperlink below to be directed to that section. POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction An enzyme is a chemical messenger. Tyrosine kinases are enzymes within cells. They serve as on/off switches for many of the cells’ functions. One of their most important roles is to help send signals telling a cell to grow. If there is a genetic change that leaves the switch permanently on, cells grow without stopping and tumors form. Multiple tyrosine kinase inhibitors block the “grow” signal in specific types of tumors. This policy discusses when multiple receptor tyrosine kinase inhibitors may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab.
    [Show full text]
  • Acute Myeloid Leukemia
    Kantarjian et al. Blood Cancer Journal (2021) 11:41 https://doi.org/10.1038/s41408-021-00425-3 Blood Cancer Journal REVIEW ARTICLE Open Access Acute myeloid leukemia: current progress and future directions Hagop Kantarjian 1, Tapan Kadia 1, Courtney DiNardo 1, Naval Daver 1, Gautam Borthakur 1, Elias Jabbour1, Guillermo Garcia-Manero 1, Marina Konopleva 1 and Farhad Ravandi1 Abstract Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions. Introduction regimens consisting of all trans-retinoic acid (ATRA) and Progress in understanding the pathophysiology and arsenic trioxide in acute promyelocytic leukemia (APL) – improving the therapy of acute myeloid leukemia (AML) resulted in cure rates of 90%8 12. In core-binding factor is now occurring at a rapid pace. The discovery of the (CBF) AML, adding gemtuzumab ozogamicin (CD33-tar- 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; activity of cytarabine (ara-C) and of anthracyclines in geted monoclonal antibody conjugated to the calicheamicin AML, and combining them in the 1970’s, into what is payload) to high-dose cytarabine-based chemotherapy – known as the “3 + 7 regimen” (3 days of daunorubicin + increased the long-term survival rate from 50% to 75+%13 17.
    [Show full text]
  • Gilteritinib
    Gilteritinib DRUG NAME: Gilteritinib SYNONYM(S): ASP22151 COMMON TRADE NAME(S): XOSPATA® CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Gilteritinib is a small molecule, multi-targeted oral tyrosine kinase inhibitor. It inhibits receptor signaling and proliferation in cells that express FMS-like tyrosine kinase 3 (FLT3), including FLT3-internal tandem duplication (ITD), tyrosine kinase domain mutations (TKD) FLT3-D835Y and FLT3-ITD-D835Y. Gilteritinib also induces apoptosis in cancer cells expressing FLT3-ITD.1-3 PHARMACOKINETICS: Oral Absorption Tmax: 4-6 h (fasted state) food effect: high-fat, high-calorie food intake reduces Cmax by 26% and delays Tmax by 2 h Distribution extensive tissue distribution cross blood brain barrier? no information found volume of distribution central: 1092 L; peripheral: 1100 L plasma protein binding 90% (primarily serum albumin) Metabolism primarily by CYP 3A4 active metabolite(s) M17 (via N-dealkylation and oxidation), M16 and M10 (via N-dealkylation) inactive metabolite(s) no information found Excretion mainly fecal elimination urine 16.4% feces 64.5% terminal half life 113 h clearance 14.85 L/h Adapted from standard reference2,3 unless specified otherwise. USES: Primary uses: Other uses: *Leukemia, acute myeloid *Health Canada approved indication SPECIAL PRECAUTIONS: Caution: • QT interval prolongation has been reported; monitor ECG and electrolytes in patients with known risk factors and correct hypokalemia and/or hypomagnesemia prior to treatment2,3 BC Cancer Drug Manual©. All rights reserved. Page 1 of 6 Gilteritinib This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
    [Show full text]
  • Is Recommended by the National Comprehensive Cancer Network® (NCCN ®)1
    Gilteritinib (XOSPATA) is recommended by the National Comprehensive Cancer Network® (NCCN ®)1 Gilteritinib (XOSPATA) is the only Category 1 recommendation for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a FLT3 mutation in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia1*† FLT3, FMS-like tyrosine kinase 3 *Published 11-12-2020.1 †Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1 WARNING: DIFFERENTIATION SYNDROME Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. Indication XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Select Safety Information Contraindications XOSPATA is contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients. Anaphylactic reactions have been observed in clinical trials. Please see additional Important Safety Information on pages 7 and 8 and click here for Full Prescribing Information, including BOXED
    [Show full text]